Increased Serum Neurofilament Light Chain Levels in Parkinson's Disease Patients Carrying the p.A53T SNCA Mutation: Data from the Parkinson's Progression Markers Initiative Study.

Key Points

• The study aims to evaluate neurofilament levels in Parkinson's disease patients with the A53T SNCA mutation.
• Data sourced from the Parkinson's Progression Markers Initiative study.
• Serum neurofilament light chain levels were measured in A53T-PD patients.
• Patients with the A53T mutation showed elevated levels of neurofilament light chain (NfL).
• High NfL levels may serve as key biomarkers for clinical trials with disease-modifying agents.